Live Analyst Rating Changes 26423 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Paul Choi
GS

Paul Choi

Goldman Sachs
Wall Street Analyst
★★★☆☆
#1743
on 13Foresight · ranked by our own returns
49%
Success Rate
+2.1%
Average Return
24 of 49 calls profitable · +31.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 49% of Paul Choi's ratings turned a profit when each position was held for 1 year — averaging +2.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

33 Buy 20 Hold 6 Sell
Paul's Stock Coverage 36 ratings · 2026-08-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
HR
Healthcare Realty Trust
 Aug 16, 2026 HOLD Hold
+11.1% avg upside
24 analysts
$14.00
27.83% Downside
 +0.9% ·
EWTX
Edgewise Therapeutics
 Aug 11, 2026 HOLD Strong Buy
+4.8% avg upside
15 analysts
$36.00
16.93% Downside
 -1.3% ·
CYTK
Cytokinetics
 Aug 07, 2026 BUY Strong Buy
+17.0% avg upside
36 analysts
 — -3.4% ·
EXEL
Exelixis
 Aug 05, 2026 BUY Buy
-19.7% avg upside
34 analysts
$64.00
19.20% Upside
 -4.1% ·
URGN
Urogen Pharma
 Aug 05, 2026 HOLD Strong Buy
-0.5% avg upside
16 analysts
$48.00
2.63% Upside
 +5.4% ·
PTCT
PTC Therapeutics
 Jul 30, 2026 SELL Buy
+14.8% avg upside
29 analysts
$70.00
0.84% Downside
 +4.6% ·
KNSA
Kiniksa Pharmaceuticals
 Jul 30, 2026 BUY Strong Buy
-2.1% avg upside
11 analysts
$90.00
14.62% Upside
 -1.8% ·
ASND
Ascendis Pharma
 Jul 27, 2026 BUY Strong Buy
+9.5% avg upside
25 analysts
$300.00
17.68% Upside
 -1.9% ·
HCM
HUTCHMED
 Jul 23, 2026 HOLD Buy
+144.7% avg upside
9 analysts
$14.00
11.50% Upside
 +15.3% ·
VERA
Vera Therapeutics
 Jun 05, 2026 BUY Strong Buy
+119.5% avg upside
19 analysts
$90.00
187.99% Upside
 -3.2% ·
RGNX
RegenXBio
 May 14, 2026 HOLD Strong Buy
+238.0% avg upside
22 analysts
$10.00
9.49% Downside
 +72.4% ·
CRVS
Corvus Pharmaceuticals
 May 14, 2026 BUY Strong Buy
+77.1% avg upside
14 analysts
$40.00
179.22% Upside
 +9.0% ·
ARVN
Arvinas Holding Company
 May 12, 2026 SELL Buy
+215.4% avg upside
28 analysts
$6.00
33.45% Downside
 +3.5% ·
BBIO
BridgeBio Pharma
 May 08, 2026 BUY Strong Buy
+14.2% avg upside
34 analysts
$116.00
39.94% Upside
 +23.4% ·
LNTH
Lantheus
 May 07, 2026 HOLD Buy
-19.2% avg upside
21 analysts
$94.00
6.28% Downside
 +10.9% ·
VIR
Vir Biotechnology
 May 06, 2026 BUY Strong Buy
+178.4% avg upside
16 analysts
$21.00
127.94% Upside
 -11.4% ·
PHAT
Phathom Pharmaceuticals
 Apr 30, 2026 HOLD Strong Buy
+201.4% avg upside
14 analysts
 — -23.2% ·
XENE
Xenon
 Mar 10, 2026 BUY Strong Buy
+4.2% avg upside
28 analysts
$75.00
25.64% Upside
 +4.2% ·
AMRN
Amarin
 Feb 25, 2026 SELL Hold
-40.2% avg upside
18 analysts
$12.00
14.67% Downside
 -0.1% ·
GOSS
Gossamer Bio
 Feb 24, 2026 HOLD Buy
+4218.7% avg upside
17 analysts
$0.50
217.51% Upside
 -65.5% ·
LINK
Interlink Electronics
 Feb 11, 2025 HOLD Strong Buy
+98.3% avg upside
16 analysts
 — -25.2% ·
PMVP
PMV Pharmaceuticals
 Dec 19, 2024 HOLD Strong Buy
+1030.4% avg upside
12 analysts
 — -17.3% ·
KYNB
Kyntra Bio
 Dec 19, 2024 HOLD Buy
+335.2% avg upside
15 analysts
 — -2.8% ·
BMRN
BioMarin Pharmaceutical
 Jun 04, 2024 BUY Strong Buy
+40.9% avg upside
52 analysts
 — -29.1% ·
HK:0013
HUTCHMED (China)
Nov 10, 2023 HOLD Buy
+499.6% avg upside
6 analysts
$133.32
575.42% Upside
 -6.5% ·
FHTX
Foghorn Therapeutics
 Jun 28, 2023 BUY Strong Buy
+69.9% avg upside
17 analysts
$19.00
170.97% Upside
 -33.1% ·
SPRY
ARS Pharmaceuticals
 Apr 03, 2022 HOLD Strong Buy
+283.0% avg upside
12 analysts
$3.50
36.47% Downside
 +95.4% ·
PBYI
Puma Biotechnology
 Nov 05, 2021 HOLD Hold
+363.3% avg upside
11 analysts
$7.00
23.11% Downside
 -32.4% ·
KRRO
Korro Bio
 Sep 22, 2021 HOLD Strong Buy
+109.0% avg upside
19 analysts
$9.00
30.53% Downside
 · ·
DNTH
Dianthus Therapeutics
 Mar 04, 2021 BUY Strong Buy
-10.5% avg upside
29 analysts
$17.00
84.56% Downside
 -80.5% ·
ARRY
Array Technologies
 Nov 09, 2020 BUY Buy
+212.9% avg upside
38 analysts
$50.00
961.66% Upside
 -48.6% ·
ODTC
Odonate
 Aug 24, 2020 SELL Hold
-99.9% avg upside
3 analysts
 — · ·
NBIX
Neurocrine
 Jun 29, 2020 HOLD Strong Buy
+22.3% avg upside
37 analysts
$135.00
11.75% Downside
 -22.8% ·
NKTR
Nektar Therapeutics
 Mar 30, 2020 HOLD Strong Buy
+0.6% avg upside
26 analysts
$20.00
73.19% Downside
 +8.0% ·
INCY
Incyte
 Nov 01, 2017 BUY Buy
-14.2% avg upside
48 analysts
$165.00
29.78% Upside
 -36.6% ·
LLY
Eli Lilly & Co
 Apr 07, 2017 BUY Strong Buy
-16.5% avg upside
48 analysts
$90.00
92.84% Downside
 -7.5% ·
🔒 31 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Paul Choi — Frequently Asked Questions
How accurate are Paul Choi's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Paul's ratings were profitable over a one-year hold, with an average return of +2.1% per rating, or +31.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Paul ranked on 13Foresight?
Paul Choi is currently ranked #1743 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Paul cover?
Paul most recently has ratings on HR, EWTX, CYTK, EXEL, URGN, PTCT, KNSA, ASND, HCM, VERA, RGNX, CRVS and 24 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.